MAKING MORE SENSE OF CALCIUM SCORES AND OTHER CORONARY PLAQUE ASSESSMENTS

If two people have the same total amount of coronary plaque, but one has mostly calcified plaque while the other has predominantly noncalcified plaque, who is at higher risk of having a heart attack?
You might assume the person with more noncalcified or "soft" plaque, but the answer isn't necessarily that straightforward. Understanding why reveals some important things about how atherosclerosis develops, progresses, and responds to treatment.
Not All Calcium Is Created Equal
For starters, calcium isn't always a sign of plaque stability or instability.
Large, dense areas of calcification are generally more stable plaque, but smaller, scattered areas of calcification, especially what are called microcalcifications within thin fibrous caps, may actually contribute to plaque vulnerability.
Likewise, noncalcified plaque isn't always unstable. Some contains large lipid-rich necrotic cores and other features associated with rupture risk, while other noncalcified plaques may actually be mostly fibrous and relatively stable. While it is true that on average it may be the case, identifying plaque as "hard" or "soft" doesn't always tell us enough about its actual risk. Interestingly, the MESA study found that among people with similar volumes of coronary calcium, those with higher calcium density had lower rates of cardiovascular events. However, there's an important distinction: MESA compared calcium volume, not total plaque volume, which includes noncalcified plaque. So while denser calcium may reflect a more favorable plaque phenotype, we can't necessarily conclude that two people with identical total plaque burdens have different risks simply because one has more calcification.
HOWEVER- PLEASE NOTE: What I am saying here is much more applicable to an initial screen done before treatment starts. If someone gets a baseline CIMT ultrasound done, for example, there is less certainty about the vulnerability of the soft plaque see, and the stability of the mixed or calcified plaque seen. BUT, if they then start treatment, especially treatment that involves direct and significant LDL lowering, and then we see the plaque the next time we do a CIMT test has changed from soft to partially calcified ('heterogenous'), or from partially calcified to fully calcified, this is much more likely to be a sign the plaque is getting more stable because there is a direct treatment involved that is likely contributing to that.
Why Do Some Plaques Calcify While Others Don't?
Calcification often develops as atherosclerosis progresses, but it's not simply a passive accumulation of calcium. It's an active biological process involving inflammation, cellular injury, vascular smooth muscle cells, and changes in the arterial wall. Age, genetics, diabetes, kidney function, and other factors can influence this process. This helps explain why two people with similar amounts of coronary plaque might have very different calcium scores.
It also raises an important question: Are we sometimes interpreting differences in plaque maturity and composition as differences in the overall amount of disease?
Potentially, yes.
A Calcium Score of Zero Doesn't Mean No Disease
This is particularly important in younger individuals. A study published in JAMA Cardiology found that among patients with obstructive coronary artery disease (CAD), a much higher proportion of younger patients had CAC scores of zero compared with older adults. In other words, significant coronary narrowing can develop before measurable calcification appears.
But here's the interesting part.
Even if they have a significantly sized coronary blockage somewhere, if they still have CAC = 0, these people often have relatively low near-term cardiovascular event rates. One likely explanation is that their overall burden of atherosclerosis is often relatively low, despite having a focal area of significant narrowing. This illustrates an important distinction: the severity of an individual blockage, total plaque burden, and future cardiovascular event risk are related, but they're not interchangeable measurements.
And importantly, low near-term risk doesn't necessarily mean low lifetime risk.
A younger person with CAC = 0 but substantial noncalcified plaque may have relatively low risk over the next several years while still facing meaningful cumulative risk over the following decades.
Why Can Calcium Increase During Cholesterol-Lowering Treatment?
Here's another interesting aspect of plaque biology. Studies have demonstrated that effective LDL-lowering therapy can reduce lipid-rich and noncalcified plaque while increasing certain measures of calcification or calcium density. This is particularly relevant to statin therapy. Rather than simply making plaque disappear, treatment can change its composition, potentially shifting it toward a more stable type. Experimental research has also demonstrated that cholesterol lowering can influence specific smooth muscle cell–derived populations involved in plaque growth.
Of course, we shouldn't oversimplify this by saying statins simply turn soft plaque into hard plaque, or assume that increasing calcification itself is responsible for reducing cardiovascular events. But the implications are important. An increasing calcium score during effective treatment doesn't mean that cardiovascular risk is increasing. On the flip side, increasing CAC in someone who is untreated is generally reflecting increasing overall atherosclerotic burden and higher risk.
In other words, context matters.
Looking Beyond Calcium Scores
All of this helps explain why I believe coronary CT angiography (CCTA), when clinically appropriate, can provide valuable additional information. Unlike conventional calcium scoring, CCTA allows us to assess both calcified and noncalcified plaque, the severity of coronary narrowing, and certain higher-risk plaque characteristics. Newer quantitative and AI-assisted plaque assessments like Cleerly and Heartflow can provide even more detailed information about plaque burden and composition, although the clinical utility of some newer measurements is still being established. Nonetheless, this doesn't mean everyone needs a CCTA. CAC remains an excellent and extensively validated tool for general cardiovascular risk assessment.
For example, in the MESA study, 10-year cardiovascular event rates ranged from approximately 1.3–5.6% among people with CAC = 0, compared with 13.1–25.6% among those with CAC scores above 300. Those are substantial differences. But CAC and CCTA answer somewhat different questions, and neither provides a complete picture of cardiovascular risk.
My Bottom Line
Two people with the same total amount of coronary plaque can have different risks depending on plaque composition, distribution, vulnerability, disease stage, and the time horizon we're considering. A calcium score of zero doesn't necessarily mean there's no atherosclerosis, and a higher calcium score doesn't automatically mean every plaque is more dangerous. Likewise, increasing calcification during effective treatment doesn't necessarily mean coronary disease is getting worse.
Ultimately, we need to consider the entire picture, including plaque burden and characteristics, ApoB exposure, blood pressure, metabolic health, inflammation, and other individual risk factors.
The goal isn't simply to lower a calcium score, eliminate every blockage, or make every plaque look a certain way. The goal is to prevent heart attacks, strokes, and cardiovascular death.
And understanding what's actually happening inside our arteries is an important part of getting there, which is not possible unless we TEST AND DON'T GUESS. If this type of content interests you, please consider taking my upcoming, 6 week, online group coaching class on heart attack and stroke prevention. We do deep dives into various related topics and participants come away with a better grasp on what causes this disease, how to best assess for it, and most importantly, how to prevent and treat it in the most comprehensive way possible. More info is a the link below. Next course starts December 2nd! The F.L.O.W. Method Program for Heart Attack and Stroke Prevention




